Get Started

NXGLW

NASD NexGel, Inc - Warrant
Nov 10, 2026 · 6:40 PM ET LAST TRADE Market Closed

$0.0051 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0051, and at the day’s high of $0.0100

YTD change
-97.83%
vs 20-day SMA
-48.60%
vs 200-day SMA
-96.85%

Price ranges

Previous day
$0.0064 $0.0070
open $0.0070 close $0.0064
-$0.0006 (-8.57%)
Today
$0.0050 $0.0100
open $0.0076 now $0.0051
-$0.0025 (-32.89%)
Past week
$0.0051 $0.0139
from $0.0099 now $0.0051
-$0.0048 (-48.48%)
Past month
$0.0050 $0.0148
from $0.0124 now $0.0051
-$0.0073 (-58.87%)
This year
$0.0050 $0.2351
from $0.2351 now $0.0051
-$0.2300 (-97.83%)

Price & Performance

-0.04 (-86.94%) / 6M

$0.0024$0.0219$0.0415$0.0610May 11Aug 13Nov 9

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 99.6% away from all-time highs of $1.3300
  • NXGLW is down 98% since the beginning of the year
  • NXGLW is down 98% over the past 12 months
  • NXGLW is down 59% over the past 1 month

NXGLW reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -97.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable N/A
EPS N/A
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A

Balance sheet & scale

IncomeN/A
RevenueN/A
CashN/A
DebtN/A
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap N/A

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,411.95 +4.28%
JNJ Johnson & Johnson $282.11 +2.13%
AZN AstraZeneca PLC Sponsored ADR $189.39 +1.59%
ABBV AbbVie, Inc. $293.30 +0.68%
MRK Merck & Co., Inc. $148.76 +1.38%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.